Waverley Pharma, Inc. (WAVE) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Intellipharmaceutics International, Inc.

Universal Ibogaine, Inc.

Waverley Pharma, Inc.

Marvel Biosciences Corp.

Tryp Therapeutics, Inc.

RepliCel Life Sciences, Inc.

Appili Therapeutics, Inc.

Algernon Pharmaceuticals, Inc.

MYND Life Sciences, Inc.

EGF Theramed Health Corp.

Aequus Pharmaceuticals, Inc.

Why is Waverley Pharma, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate 12.72% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -0.81

The company has declared Negative results for the last 8 consecutive quarters

PRE-TAX PROFIT(Q) At CAD -0.24 MM has Fallen at -135.16%
NET PROFIT(Q) At CAD -0.24 MM has Fallen at -136.78%
INTEREST(HY) At CAD 0.09 MM has Grown at 15.74%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 50.00%, its profits have risen by 70.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Waverley Pharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Waverley Pharma, Inc.

50.0%

-0.09

278.24%

S&P/TSX 60

21.87%

1.42

15.38%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

4.36%

EBIT Growth (5y)

12.72%

EBIT to Interest (avg)

-0.81

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.32

Sales to Capital Employed (avg)

0.60

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.57

EV to EBIT

-4.32

EV to EBITDA

-4.32

EV to Capital Employed

4.32

EV to Sales

2.87

PEG Ratio

Dividend Yield

ROCE (Latest)

-18.23%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bullish

Bollinger Bands

Bearish

Sideways

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

NET SALES(HY)

At CAD 0.66 MM has Grown at 2,849.81%

OPERATING CASH FLOW(Y)

Highest at CAD -0.46 MM

NET PROFIT(HY)

Higher at CAD -0.27 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 28.2 times

-11What is not working for the Company

PRE-TAX PROFIT(Q)

At CAD -0.24 MM has Fallen at -135.16%

NET PROFIT(Q)

At CAD -0.24 MM has Fallen at -136.78%

INTEREST(HY)

At CAD 0.09 MM has Grown at 15.74%

RAW MATERIAL COST(Y)

Grown by 66.8% (YoY

Here's what is working for Waverley Pharma, Inc.

Net Sales

At CAD 0.66 MM has Grown at 2,849.81%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (CAD MM)

Operating Cash Flow

Highest at CAD -0.46 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Debtors Turnover Ratio

Highest at 28.2 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for Waverley Pharma, Inc.

Pre-Tax Profit

At CAD -0.24 MM has Fallen at -135.16%

over average net sales of the previous four periods of CAD -0.1 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (CAD MM)

Net Profit

At CAD -0.24 MM has Fallen at -136.78%

over average net sales of the previous four periods of CAD -0.1 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (CAD MM)

Interest

At CAD 0.09 MM has Grown at 15.74%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)

Raw Material Cost

Grown by 66.8% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales